Calycosin Inhibit PANoptosis and Alleviate Brain Damage: A Bioinformatics and Experimental Verification Approach by Huiyan An (20959966)

“…Calycosin, a natural product with diverse biological activities, has demonstrated a significant reduction in neuronal death caused by ischemic brain injury by modulating multiple cell death pathways. …”

<i>CTSZ</i> SNPs significantly associated with TB severity in Ugandan household contact study cohorts, sorted by ascending <i>p</i>-value. by Rachel K. Meade (22216529)

The normal force between two particles with different equivalent diameters for P3: (a) hertznormal contact force; (b) normal viscous contact force. by Yongfeng Zhu (7361045)

Test soil parameters. by Yonggang Huang (223155)

“…The swelling pressure of reinforced expansive soil exhibits a significant negative correlation with both the UHMWPE content (<i>p</i> < 0.05) and its length. …”

Influence of UHMWPE length on swelling pressure. by Yonggang Huang (223155)

“…The swelling pressure of reinforced expansive soil exhibits a significant negative correlation with both the UHMWPE content (<i>p</i> < 0.05) and its length. …”

UHMWPF parameters. by Yonggang Huang (223155)

“…The swelling pressure of reinforced expansive soil exhibits a significant negative correlation with both the UHMWPE content (<i>p</i> < 0.05) and its length. …”

Influence of UHMWPE content on swelling pressure. by Yonggang Huang (223155)

“…The swelling pressure of reinforced expansive soil exhibits a significant negative correlation with both the UHMWPE content (<i>p</i> < 0.05) and its length. …”

Soil partice-size distribution. by Yonggang Huang (223155)

“…The swelling pressure of reinforced expansive soil exhibits a significant negative correlation with both the UHMWPE content (<i>p</i> < 0.05) and its length. …”

Sampling point (Source: by Yonggang Huang (223155)

Thermal gravimetric analyses and the first derivative for the obtained data for the PVA; (A and B) and TiO₂; (C and D) compared with the pristine kaolin. by Nasser A. M. Barakat (11705885)

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

S1 Data - by Perumal Vivekanandhan (4863484)

Subjects:

Dynamical changes in the buffer population (<i>L</i> = 1023). by Ariel Burman (20329776)